A groundbreaking study published in Neurology and reported by Drugs.com reveals that adults with type 2 diabetes who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of medications increasingly popular for blood sugar control and weight management, demonstrate a significantly reduced risk of developing epilepsy compared to those using alternative diabetes medications.
Researchers led by Dr. Ching-Yang Cheng from Chung Shan Medical University in Taiwan conducted a comprehensive retrospective cohort study analyzing data from 2015 to 2023 using the TriNetX network. The investigation compared epilepsy risk between adults newly prescribed GLP-1 RAs and those given dipeptidyl peptidase-4 inhibitors (DPP-4is), another class of type 2 diabetes medication. After applying propensity score matching to ensure fair comparison between groups, the final analysis included 452,766 patients, 226,383 in each group.
The results were striking. During the follow-up period, 1,670 patients in the GLP-1 RA group developed epilepsy, compared to 1,886 in the DPP-4i group. While these numbers seem substantial, they represent relatively low incidence rates of 2.35 percent and 2.41 percent, respectively. More importantly, GLP-1 RA users showed a significantly lower epilepsy risk with a hazard ratio of 0.84—meaning approximately 16 percent lower risk compared to those using DPP-4i medications.
The protective effect of GLP-1s remained consistent over time. At one-year follow-up, the hazard ratio was 0.71; at three years, it rose slightly to 0.81; and at five years, it remained protective at 0.82. Among the various GLP-1 medications examined, semaglutide demonstrated the strongest association with reduced epilepsy risk, with a hazard ratio of 0.68.
The findings held firm across diverse population subgroups, including variations in age and sex, suggesting the protective effect isn’t limited to specific demographics. Additionally, sensitivity analyses that excluded patients with overlapping or switching medication exposure produced similar results, strengthening confidence in the findings.
Dr. Edy Kornelius, a coauthor on the study, emphasized that while these results are compelling, they represent an important but preliminary discovery. “More research is needed, but these findings support the theory that GLP-1 drugs may have neurological benefits beyond controlling blood sugar,” Kornelius stated. He also offered important context: the findings don’t suggest that DPP-4 inhibitors are harmful, nor do they definitively confirm that GLP-1 drugs provide brain protection.
The implications of this research extend beyond typical diabetes management. GLP-1 receptor agonists have already gained widespread attention for their effectiveness in blood glucose regulation and their demonstrated benefits in weight loss. The possibility of neurological protective effects opens new avenues for understanding these medications’ mechanisms of action and potential applications.
This study adds to growing evidence that GLP-1 drugs may offer benefits extending beyond metabolic control, though researchers caution that individual results vary significantly. People with type 2 diabetes should continue consulting their healthcare providers for personalized medical advice regarding medication choices and epilepsy risk management.
